APA (7th ed.) Citation

Mouri, A., Kaira, K., Shiono, A., Yamaguchi, O., Murayama, Y., Kobayashi, K., & Kagamu, H. (2019). Clinical significance of primary prophylactic pegylated‐granulocyte‐colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non‐small cell lung cancer. Wiley.

Chicago Style (17th ed.) Citation

Mouri, Atsuto, Kyoichi Kaira, Ayako Shiono, Ou Yamaguchi, Yoshitake Murayama, Kunihiko Kobayashi, and Hiroshi Kagamu. Clinical Significance of Primary Prophylactic Pegylated‐granulocyte‐colony Stimulating Factor After the Administration of Ramucirumab Plus Docetaxel in Patients with Previously Treated Non‐small Cell Lung Cancer. Wiley, 2019.

MLA (8th ed.) Citation

Mouri, Atsuto, et al. Clinical Significance of Primary Prophylactic Pegylated‐granulocyte‐colony Stimulating Factor After the Administration of Ramucirumab Plus Docetaxel in Patients with Previously Treated Non‐small Cell Lung Cancer. Wiley, 2019.